ArriVent BioPharma, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 5 Aug 2026Shareholders voted on who runs the company and checks its finances, which affects how well the business is managed.
The company can now raise cash by selling stock, which helps fund operations but dilutes existing shareholders' ownership.
This legal document lets the company sell shares gradually when needed, providing flexible funding for the business.
Quarterly earnings show whether the company is spending money wisely and making progress toward profitability.
Quarterly earnings show whether the company is spending money wisely and making progress toward profitability.
Press releases share company news that may affect stock price and investor confidence in the business.
Annual reports show the complete picture of company finances, debts, and business operations over the whole year.
Stocky reads ArriVent BioPharma, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
ArriVent BioPharma, Inc.'s most recent tracked filing was a 8-K on 22 Jun 2026: Stockholders elect three directors, ratify auditor PwC.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 5 Aug 2026.